NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Zynex, Inc. (OTCMKTS: ZYXIQ) (“Zynex” or the “Company”) inclusive on behalf of all persons and entities that purchased or otherwise acquired Zynex shares between February 25, 2021 and December 15, 2025, both dates inclusive (the "Class Period"). Investors have until April 21, 2026, to seek appointments as lead plaintiff. PLEASE CLICK HERE TO JOIN THE CASE AND SUB ...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Gemini Space Station, Inc. ("Gemini†or the "Company†) (NASDAQ:GEMI) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On September 12, 2025, Gemini conducted its initial public offering, selling 15,937,501 shares of Class A co. ...

New York, New York--(Newsfile Corp. - February 20, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Wealthfront Corporation (NASDAQ: WLTH) for potential violations of the federal securities laws. If you invested in Wealthfront, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/wealthfront-corporation-class-action.Why is Wealthfront Being Investigated for Violations of the Federal Securities Laws? Wealthfront is an onl ...

Core Viewpoint - Kyndryl Holdings, Inc. is under investigation for potential violations of federal securities laws following the sudden departure of its CFO and General Counsel, alongside the receipt of voluntary document requests from the SEC [1] Company Developments - On February 9, 2026, Kyndryl announced the immediate departure of its CFO and General Counsel [1] - The company is currently reviewing its documents in response to requests from the SEC [1]

Core Viewpoint - A class action lawsuit has been filed against DeFi Technologies, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from May 12, 2025, to November 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased DeFi Technologies securities during the specified Class Period [2]. - The Complaint alleges that Defendants made false and misleading statements and failed to disclose critical issues affecting the company, including delays in executing its DeFi arbitrage strategy, competition from other digital asset treasury companies, and an inability to meet revenue guidance for fiscal year 2025 [3]. Group 2: Implications for Investors - Investors are encouraged to join the class action and can request to be appointed as lead plaintiff until January 30, 2026 [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Firefly Aerospace Inc. due to allegations of misleading statements and operational issues that have negatively impacted the company's stock performance and investor confidence [4][6]. Group 1: Company Overview - Firefly Aerospace Inc. conducted its initial public offering (IPO) on August 7, 2025, selling 19.296 million shares at a price of $45.00 per share [7]. - The company reported a significant loss of $80.3 million, or $5.78 per share, for the second quarter of 2025, which is an increase from a loss of $58.7 million, or $4.60 per share, in the same quarter of 2024 [8]. Group 2: Financial Performance - Firefly's revenue for the second quarter of 2025 was $15.55 million, which fell short of analyst estimates of $17.25 million and represented a 26.2% decrease from the same quarter in 2024 [8]. - The revenue from Firefly's Spacecraft Solutions business segment was only $9.2 million, indicating a 49% year-over-year decrease [8]. Group 3: Stock Performance and Legal Implications - Following the financial results announcement, Firefly's stock price dropped by $7.58 per share, or 15.31%, closing at $41.94 on September 23, 2025 [9]. - After a subsequent announcement regarding a failure in the Alpha Flight 7 rocket test, the stock price fell further by $7.66 per share, or 20.73%, closing at $29.30 on September 30, 2025 [11]. Group 4: Legal Action and Class Action Details - A federal securities class action has been filed against Firefly, with a deadline of January 12, 2026, for investors to seek the role of lead plaintiff [4]. - The complaint alleges that Firefly and its executives made false statements regarding the demand for its offerings and the operational readiness of its rocket program, which could have a material negative impact on the company [6].

Core Viewpoint - The complaint against Skye Bioscience alleges that the company and its executives misled investors regarding the effectiveness and prospects of nimacimab, leading to significant stock price decline following the release of disappointing clinical trial results [2][3]. Group 1: Allegations and Impact - The complaint claims that nimacimab was less effective than previously communicated, resulting in overstated clinical, regulatory, and commercial prospects [2]. - Following the announcement of the Phase 2a study results, Skye's stock price dropped by $2.85 per share, or 60%, closing at $1.90 per share on October 6, 2025 [3]. Group 2: Legal Proceedings - The lead plaintiff in the class action is the investor with the largest financial interest, who will oversee the litigation on behalf of the class [4]. - Any member of the putative class can apply to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [4]. Group 3: Call for Information - The law firm Faruqi & Faruqi encourages individuals with information regarding Skye's conduct to come forward, including whistleblowers and former employees [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of violations of federal securities laws, particularly concerning misleading statements about its product SLK compared to BIMZELX [3][5]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against MoonLake [3]. - The complaint alleges that MoonLake and its executives made false and misleading statements regarding the efficacy and clinical benefits of SLK compared to traditional monoclonal antibodies [5]. - Investors who suffered losses between March 10, 2024, and September 29, 2025, are encouraged to contact the firm to discuss their legal options [1][8]. Group 2: Stock Performance and Impact - Following the announcement of disappointing results from the Phase 3 VELA program on September 28, 2025, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [6]. - The results indicated that SLK did not demonstrate competitive efficacy relative to BIMZELX, which contributed to the significant drop in stock price [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's new Inspire V device and its market demand [2][5]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in Inspire Medical to contact them directly to discuss their legal options [1]. - There is a deadline of January 5, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Inspire Medical [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [8]. Group 2: Company Performance and Issues - Inspire Medical announced significant setbacks in the launch of its Inspire V device, citing delays due to incomplete training and onboarding at treatment centers [6]. - The company faced billing and reimbursement challenges, as necessary software updates for claims processing were not effective until July 1, 2025, leading to continued use of the older Inspire IV system [6]. - Inspire reported weak demand and excess inventory for the Inspire V, resulting in a more than 80% cut in its 2025 earnings guidance [7]. Group 3: Market Impact - Following the announcement of these issues, Inspire Medical's stock price dropped over 32% in one day, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025, resulting in a loss of approximately $1.2 billion in market capitalization [7].

Core Viewpoint - Edelson Lechtzin LLP is investigating CarMax, Inc. for potential violations of federal securities laws due to allegations of providing misleading business information to investors [1] Group 1 - The investigation is being conducted by a national class action law firm [1] - The focus of the investigation is on CarMax, Inc., which is listed on the NYSE under the ticker KMX [1] - Allegations suggest that CarMax may have misled the investing public regarding its business information [1]